Posted on June 12, 2010 by Sitemaster
Back in 2008 we first mentioned the initiation of clinical trials of a drug called Apoptone or HE3235 in men with hormone-refractory prostate cancer. Data on the development of Apoptone was another item on the agenda at the annual meeting of the American Society of Clinical Oncology (ASCO) earlier this week. … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: Apoptone, castration-resistant, HE3235, hormone refractory | Leave a comment »
Posted on January 27, 2009 by Sitemaster
Today’s news deals with such items as:
- Toxicities associated with hypofractionated, intensity-modulated radiation therapy
- Incidental prostate cancer in male patients undergoing radical cystoprostatectomy for treatment of bladder cancer
- A Spanish review of photodynamic therapy
- A proposed mechanism of action for the investigational drug Apoptone™ (HE3235) … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: Apoptone, cystoprostatectomy, HE3235, hypofractionated, IMRT, photodynamic therapy | Leave a comment »
Posted on July 31, 2008 by Sitemaster
News items today are focused on information about:
- a new way of approaching treatment of hormone-refractory disease
- the initial clinical trials of a new drug candidate in hormone-refractory patients
- the association between hospital and surgeon volume and patient outcomes after radical prostatectomy. … MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: Apoptone, cancer, HE3235, hormone refractory, hospital, news, prostate, prostatectomy, radical, update, volume | Leave a comment »